- BioDuro has opened a new solid-phase peptide synthesis scale-up laboratory at its Shanghai campus.
- The facility supports kilogram-scale peptide production, advancing the company’s CRDMO services.

BioDuro, a Contract Research, Development, and Manufacturing Organization (CRDMO), has announced the opening of a fully-automated solid-phase peptide synthesis scale-up laboratory in Shanghai, China. Located at the Zhangjiang High-tech Park campus, the new facility enhances BioDuro’s peptide manufacturing capabilities, meeting growing global demand for scalable and efficient peptide production.
Equipped with advanced automated synthesizers, cleavage systems, and freeze-drying technology, the laboratory supports peptide synthesis scale-up to 800 mmol. It is designed to produce diverse peptide molecules, including linear peptides, cyclic peptides, and peptide drug conjugates (PDC).
The Shanghai facility complements BioDuro’s peptide discovery synthesis centre in Beijing, which focuses on early-stage research and development. Together, these campuses create a seamless integration of services, from discovery to development. “The opening of this new laboratory provides BioDuro’s customers with a significant step forward in scaling their candidates,” said Dr. Armin Spura, CEO of BioDuro.
BioDuro’s integrated peptide platform combines biology and Drug Metabolism and Pharmacokinetics (DMPK) services, offering a comprehensive, one-stop solution for peptide therapeutics. This approach streamlines processes and collaboration, accelerating the development of life-changing therapies.